Pharmalex Nordic ApS: Financial statements 2017
CVR: 37541540
Source: annual report 2017, Danish Business Authority
01/01/2017 – 31/12/2017
Pharmalex Nordic ApS (CVR 37541540) has filed annual accounts for 2017. In 2017, the company reported a gross profit of DKK 99,661 and a net result of DKK 494,960. Equity in the 2017 report amounted to DKK 2,853,198. The solvency ratio was 36.5%. The company had 1 employee in the financial year.
- Gross Profit
- DKK 99,661
- Profit/Loss
- DKK 494,960
- Equity
- DKK 2,853,198
- Total Assets
- DKK 7,818,121
- Employees
- 1
Official annual report
Keep an eye on Pharmalex Nordic ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2017
Pharmalex Nordic ApS has published its interim report for the period March 16, 2016 to December 31, 2016.
As of May 3, 2017, Beierholm Godkendt Revisionspartnerselskab has been appointed auditor of Pharmalex Nordic ApS.
As of January 1, 2017, Torben Thers Nørgaard is registered as adm. dir. of Pharmalex Nordic ApS.
As of January 1, 2017, Dr. Raphael Troost is registered as director of Pharmalex Nordic ApS.
About Pharmalex Nordic ApS
Pharmalex Nordic ApS is a Danish company of the type Anpartsselskab based in Kongens Lyngby, founded in 2016. The company is registered under the industry Ikke-finansielle holdingselskaber. The management consists of Åsa Pihlblad and Christopher Gauglitz. The company is owned by AmerisourceBergen International B.V.. The company has 1 employee (2026). In 2025, the company reported a gross profit of DKK 3,533,803 and a net result of DKK 1,709,691 compared with DKK -88,447,652 the year before. Equity in the 2025 report amounted to DKK -45,957,544.